Table 1.
Patients' characteristics.
| # | Sex | Age (yrs) | EGFR type | Tissues and genetic testing | |||
|---|---|---|---|---|---|---|---|
| Before osimertinib | After osimertinib | ||||||
| 1 | F | 62 | L858R | Lung | NGS | Pleura | NGS |
| 2 | M | 85 | 19 del | SL | ARMs-PCR | Lung | NGS |
| 3 | M | 66 | 19 del | Bone | ARMs-PCR | Lung | NGS |
| 4 | F | 79 | L858R | Lung | ARMs-PCR | Lung | NGS |
| 5 | F | 89 | 19 del | Lung | NGS | Lung | NGS |
| 6 | F | 66 | 19 del | Serum | ARMs-PCR | Bone | NGS |
| 7 | M | 56 | 19 del | Lung | ARMs-PCR | Lung | NGS |
| 8 | F | 75 | 19 del | Pleura | ARMs-PCR | Pleura | NGS |
| 9 | M | 51 | 19 del | Lung | ARMs-PCR | Lung | NGS |
| Median | 66 | ||||||
SL denotes supraclavicular lymph node.